Quick Links


    Print

Beyond Daily Oral TDF/FTC as PrEP: Exploring new drugs and regimens for PrEP

October 3, 2012

PrEP researchers discussed ongoing trials of new oral PrEP interventions, including non-daily regimens (also described as “intermittent PrEP”) and new drugs such as maraviroc.

Principal investigators Bob Grant (ADAPT), Ken Mayer (NEXT-PrEP), Sheena McCormack (PROUD) and Jean-Michel Molina (ANRS Ipergay) joined the call. Their trials all seek to answer questions about strategies other than daily oral TDF/FTC and will provide important information on potential “second generation” oral PrEP.

Slides: PDF
Listen: MP3
Animation: Flash


AVAC: Global Advocacy for HIV Prevention
101 West 23rd Street   ·  New York, NY  
+1 212.796.6423 (main)   ·  avac@avac.org
Copyright 2014, All rights reserved.
Design by Lomangino Studio | Powered by Orchid Suites Orchid ver. 4.7.6.